SECURITIES AND EXCHANGE COMMISSION,

CELLCYTE GENETICS CORPORATION and

Defendants.

Plaintiff,

RONALD W. BERNINGER,

VS.

ORIGINAL

2

1

3

5

6

8

9 10

11

12

13

14

15

16

17

18 19

20

21 22

23

24 25

26

27

28

SEC V. CELLCYTE GENETICS CORP., ET AL. FINAL JUDGMENT AS TO DEFENDANT RONALD W. BERNINGER

09-CV-01263-ORD

UNITED STATES DISTRICT COURT

WESTERN DISTRICT OF WASHINGTON

AT SEATTLE

Civil Action No. C0 9-1263

[PROPOSED] FINAL JUDGMENT AS TO DEFENDANT RONALD W. BERNINGER

The Securities and Exchange Commission having filed a Complaint and Defendant Ronald W. Berninger having entered a general appearance; consented to the Court's jurisdiction over Defendant and the subject matter of this action; consented to entry of this Final Judgment without admitting or denying the allegations of the Complaint (except as to jurisdiction); waived findings of

I.

fact and conclusions of law; and waived any right to appeal from this Final Judgment:

IT IS HEREBY ORDERED, ADJUDGED AND DECREED that Defendant and Defendant's agents, servants, employees, attorneys, and all persons in active concert or participation with them who receive actual notice of this Final Judgment by personal service or otherwise are permanently restrained and enjoined from violating, directly or indirectly, Section 10(b) of the Securities

> SECURITIES AND EXCHANGE COMMISSION 44 MONTGOMERY STREET, SUITE 2600 SAN FRANCISCO, CA 94104 TELEPHONE: 415-705-2500

1	
2	
3	
4	
5	
6	
7	
8	
9	
10	
10 11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	
	Ħ

26

27

28

Exchange Act of 1934 (the "Exchange Act") [15 U.S.C. § 78j(b)] and Rule 10b-5 promulgated thereunder [17 C.F.R. § 240.10b-5], by using any means or instrumentality of interstate commerce, or of the mails, or of any facility of any national securities exchange, in connection with the purchase or sale of any security:

- (a) to employ any device, scheme, or artifice to defraud;
- (b) to make any untrue statement of a material fact or to omit to state a material fact necessary in order to make the statements made, in the light of the circumstances under which they were made, not misleading; or
- (c) to engage in any act, practice, or course of business which operates or would operate as a fraud or deceit upon any person.

II.

IT IS FURTHER ORDERED, ADJUDGED AND DECREED that Defendant and Defendant's agents, servants, employees, attorneys, and all persons in active concert or participation with them who receive actual notice of this Final Judgment by personal service or otherwise are permanently restrained and enjoined from aiding and abetting any violation of Section 13(a) of the Exchange Act [15 U.S.C. § 78m(a)] and Rules 12b-20, 13a-11 and 13a-13 promulgated thereunder [17 C.F.R. §§ 240.12b-20, 240.13a-11 and 240.13a-13] by knowingly providing substantial assistance to an issuer that has a class of securities registered pursuant to Section 12 of the Exchange Act [15 U.S.C. § 78] or is required to file reports pursuant to Section 15(d) of the Exchange Act [15 U.S.C. § 780] in failing to file with the Commission such accurate and complete reports, information, and documents as are required to be filed with the Commission pursuant to Section 13(a) of the Exchange Act [15 U.S.C. § 78m(a)] and the Commission's Rules thereunder, including but not limited to, current reports on Form 8-K [17 C.F.R. § 249.308] as prescribed by Commission Rule 13a-11 [17 C.F.R. § 240.13a-11] and quarterly reports on Form 10-Q [17 C.F.R. § 249.308a] as prescribed by Commission Rule 13a-13 [17 C.F.R. § 240.13a-13], such information and documents to contain, in addition to such information as is expressly required to be included in a statement or report to the Commission, such further material information, if any, as may be necessary to make the

-2-

TELEPHONE: 415-705-2500

required statements, in the light of the circumstances under which they are made, not misleading, as prescribed by Commission Rule 12b-20 [17 C.F.R. § 240.12b-20].

III.

IT IS FURTHER ORDERED, ADJUDGED AND DECREED that, pursuant to Section 21(d)(2) of the Exchange Act [15 U.S.C. § 78u(d)(2)], Defendant is prohibited, for five years following the date of entry of this Final Judgment, from acting as an officer or director of any issuer that has a class of securities registered pursuant to Section 12 of the Exchange Act [15 U.S.C. § 78/] or that is required to file reports pursuant to Section 15(d) of the Exchange Act [15 U.S.C. § 78o(d)].

IV.

IT IS FURTHER ORDERED, ADJUDGED AND DECREED that Defendant shall pay a civil penalty in the amount of \$50,000 pursuant to Section 21(d)(3) of the Exchange Act [15 U.S.C. § 78u(d)(3)]. Defendant shall make this payment within ten (10) business days after entry of this Final Judgment by certified check, bank cashier's check, or United States postal money order payable to the Securities and Exchange Commission. The payment shall be delivered or mailed to the Office of Financial Management, Securities and Exchange Commission, Operations Center, 6432 General Green Way, Mail Stop O-3, Alexandria, Virginia 22312, and shall be accompanied by a letter identifying Ronald W. Berninger as a defendant in this action; setting forth the title and civil action number of this action and the name of this Court; and specifying that payment is made pursuant to this Final Judgment. Defendant shall simultaneously transmit photocopies of such payment and letter to the attention of Marc J. Fagel, Regional Director, at the Commission's San Francisco Regional Office, 44 Montgomery Street, Suite 2600, San Francisco, CA 94104. Defendant shall pay post-judgment interest on any delinquent amounts pursuant to 28 U.S.C. § 1961. The Commission shall remit the funds paid pursuant to this paragraph to the United States Treasury.

V.

IT IS FURTHER ORDERED, ADJUDGED, AND DECREED that the Consent is incorporated herein with the same force and effect as if fully set forth herein, and that Defendant shall comply with all of the undertakings and agreements set forth therein.

-3-

28 SEC v. CellCyte Genetics Corp., et al.

FINAL JUDGMENT AS TO DEFENDANT RONALD W.
BERNINGER

SECURITIES AND EXCHANGE COMMISSION 44 MONTGOMERY STREET, SUITE 2600 SAN FRANCISCO, CA 94104 TELEPHONE: 415-705-2500

1	VI.
2	IT IS FURTHER ORDERED, ADJUDGED, AND DECREED that this Court shall retain
3	jurisdiction of this matter for the purposes of enforcing the terms of this Final Judgment.
4	VII.
5	There being no just reason for delay, pursuant to Rule 54(b) of the Federal Rules of Civil
6	Procedure, the Clerk is ordered to enter this Final Judgment forthwith and without further notice.
7	MAN Classic
8	Dated: Dec. 10, 2009 MAS Casmik
9	UNITED STATES DISTRICT JUDGE
10	
11	
12	
13	
14	
15 16	
17	
18	
19	
20	
21	
22	
23	
24	
25	
26	
27	

28

SEC V. CELLCYTE GENETICS CORP., ET AL. FINAL JUDGMENT AS TO DEFENDANT RONALD W. BERNINGER

-5-

27

28

SECURITIES AND EXCHANGE COMMISSION 44 MONTGOMERY STREET, SUITE 2600 SAN FRANCISCO, CA 94104 TELEPHONE: 415-705-2500